FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children

E. S. Koster, A-H. Maitland-van der Zee, R. Tavendale, S. Mukhopadhyay, S. J. H. Vijverberg, J. A. M. Raaijmakers, C. N. A. Palmer

    Research output: Contribution to journalArticlepeer-review

    60 Citations (Scopus)


    Background: The T2206C FCER2 variant was found previously to be associated with IgE levels, exacerbation rates and decreased FCER2 expression in children on inhaled corticosteroids (ICS) participating in a clinical trial. This finding has not been replicated. We sought to replicate the association between the FCER2 gene and exacerbations in children with asthma. In addition, we tested the hypothesis that the T2206C variant may be associated with other markers of steroid resistance such as asthma symptom scores and asthma medication use.

    Methods: The influence of the T2206C variant on asthma exacerbations (emergency department visits or hospitalization), symptoms scores and medication use was explored using data from two populations of asthmatic children using ICS: Pharmacogenetics of Asthma medication in Children: Medication with ANti-inflammatory effects study (n = 386) and BREATHE study (n = 939).

    Results: The T2206C variant was associated with increased risk of asthma-related hospital visits in both cohorts (OR: 1.91, 95%CI: 1.08-3.40), and meta-analysis with previously published results was highly significant (OR: 2.38, 95%CI: 1.47-3.85, P = 0.0004). The FCER2 variant was also associated with increased risk of uncontrolled asthma measured by Asthma Control Questionnaire (OR: 2.64, 95%CI: 1.00-6.98) and was associated with increased daily steroid dose (OR: 2.46, 95%CI: 1.38-4.39).

    Conclusion: The association between the FCER2 T2206C variant and asthma-related hospitalizations in steroid-treated asthma appears robust and may also be associated with other indicators of lack of ICS efficacy such as asthma symptoms and a requirement for higher daily doses of ICS. Our results suggest that the FCER2 T2206C variant might be a useful pharmacogenetic predictor of steroid refractory patients.

    Original languageEnglish
    Pages (from-to)1546-1552
    Number of pages7
    Issue number12
    Publication statusPublished - Dec 2011


    • asthma
    • exacerbations
    • FCER2
    • inhaled corticosteroids
    • pharmacogenetics
    • IGE
    • BURDEN
    • COHORT


    Dive into the research topics of 'FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children'. Together they form a unique fingerprint.

    Cite this